Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.

Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.

Cardiotoxicity of doxorubicin (DOX) remains an important health concern. DOX cardiotoxicity is cumulative-dose-dependent and begins with the first dose of chemotherapy. No biomarker for presymptomatic detection of DOX cardiotoxicity has been validated. Our hypothesis is that peripheral blood cells (...

Full description

Bibliographic Details
Main Authors: Valentina K Todorova, Issam Makhoul, Eric R Siegel, Jeanne Wei, Annjanette Stone, Weleetka Carter, Marjorie L Beggs, Aaron Owen, V Suzanne Klimberg
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4973957?pdf=render

Internet

http://europepmc.org/articles/PMC4973957?pdf=render

Similar Items